Earnings summaries and quarterly performance for ASSEMBLY BIOSCIENCES.
Executive leadership at ASSEMBLY BIOSCIENCES.
Jason A. Okazaki
Detailed
Chief Executive Officer and President
CEO
AG
Anuj Gaggar, M.D., Ph.D.
Detailed
Chief Medical Officer
JB
Jeanette Bjorkquist
Detailed
Principal Financial Officer and Principal Accounting Officer
NS
Nicole S. White, Ph.D.
Detailed
Chief Manufacturing Officer
WE
William E. Delaney IV, Ph.D.
Detailed
Chief Scientific Officer
Board of directors at ASSEMBLY BIOSCIENCES.
AE
Anthony E. Altig
Detailed
Director
GC
Gina Consylman
Detailed
Director
JG
John G. McHutchison, A.O., M.D.
Detailed
Director
LR
Lisa R. Johnson-Pratt, M.D.
Detailed
Director
RD
Robert D. Cook II
Detailed
Director
SM
Sir Michael Houghton, Ph.D.
Detailed
Director
SM
Susan Mahony, Ph.D.
Detailed
Director
TC
Tomas Cihlar, Ph.D.
Detailed
Director
WR
William R. Ringo, Jr.
Detailed
Chairman of the Board
Research analysts covering ASSEMBLY BIOSCIENCES.
Recent press releases and 8-K filings for ASMB.
Assembly Bio Announces Positive Phase 1b Results for Genital Herpes Candidates ABI-1179 and ABI-5366
ASMB
New Projects/Investments
Product Launch
- Assembly Bio (ASMB) announced positive Phase 1b clinical study results for its recurrent genital herpes candidates, ABI-1179 and ABI-5366, with both meeting or exceeding key objectives.
- ABI-1179 (50 mg weekly oral) achieved a 98% reduction in HSV-2 shedding and a 91% reduction in virologically confirmed genital lesions compared to placebo.
- ABI-5366 (350 mg weekly regimen) demonstrated a 94% reduction in HSV-2 shedding, a 98% reduction in high viral load shedding, and a 97% reduction in virologically confirmed genital lesions compared to placebo.
- The company plans to initiate a Phase 2 clinical study for ABI-5366 in mid-2026 and has begun Phase 2 enabling activities for ABI-1179, with a cash runway extending into late 2027.
Dec 8, 2025, 11:00 PM
Assembly Bio Announces Positive Interim Phase 1b Results for Genital Herpes Candidates ABI-1179 and ABI-5366
ASMB
Product Launch
New Projects/Investments
- Assembly Bio (ASMB) announced positive interim Phase 1b clinical study results for its long-acting helicase-primase inhibitor candidates, ABI-1179 and ABI-5366, for recurrent genital herpes on December 8, 2025.
- ABI-1179 demonstrated a 98% reduction in HSV-2 shedding (p<0.01) and a 91% reduction in virologically confirmed genital lesions (p<0.01) in the 50mg weekly cohort B1.
- ABI-5366 showed a 94% reduction in HSV-2 shedding (p<0.01) and a 97% reduction in virologically confirmed lesion rate (p<0.05) in the 350mg weekly cohort B2.
- Both candidates exhibited a clean safety profile with no serious adverse events or discontinuations due to treatment-emergent adverse events.
- Phase 2 enabling activities are underway for ABI-1179, and Phase 2 planning for ABI-5366 is underway with study initiation expected mid-2026.
Dec 8, 2025, 11:00 PM
Assembly Bio Announces Positive Phase 1b Results for Genital Herpes Candidates
ASMB
New Projects/Investments
- Assembly Bio announced impressive results from its Phase 1b clinical studies for long-acting helicase-primase inhibitor candidates, ABI-1179 and ABI-5366, in participants with recurrent genital herpes, with both candidates meeting or exceeding all key study objectives.
- For ABI-1179, the 50 mg weekly regimen demonstrated a 98% reduction in HSV-2 shedding and a 91% reduction in virologically confirmed genital lesions compared to placebo.
- For ABI-5366, the 350 mg weekly regimen showed a 94% reduction in HSV-2 shedding and a 97% reduction in virologically confirmed genital lesions compared to placebo.
- A monthly dosing cohort for ABI-5366 showed potent antiviral activity but suggested additional work is needed to maintain the high level of suppression seen with weekly dosing.
- The company expects to initiate a Phase 2 clinical study for ABI-5366 in mid-2026 and has begun Phase 2 enabling activities for ABI-1179. Assembly Bio's cash runway is projected to fund operations into late 2027, with potential extension beyond 2028.
Dec 8, 2025, 11:00 PM
Assembly Bio Announces Positive Phase I-B Results for Genital Herpes Candidates
ASMB
New Projects/Investments
Product Launch
- Assembly Bio announced positive Phase I-B clinical study results for its long-acting helicase-primase inhibitor candidates, ABI-1179 and ABI-5366, in participants with recurrent genital herpes.
- ABI-1179 (50 mg weekly) demonstrated a 98% reduction in HSV-2 shedding and a 91% reduction in virologically confirmed lesions compared to placebo.
- ABI-5366 (350 mg weekly) showed a 94% reduction in HSV-2 shedding and a 97% reduction in virologically confirmed lesions compared to placebo.
- While the monthly dosing cohort for ABI-5366 showed a 76% reduction in HSV-2 viral shedding, the company plans further optimization to maintain higher suppression levels.
- Assembly Bio expects to initiate a Phase II clinical study of ABI-5366 in mid-2026 and has begun Phase II enabling activities for ABI-1179, with a cash runway funding the company into late 2027.
Dec 8, 2025, 11:00 PM
Assembly Biosciences Reports Positive Interim Phase 1b Results for HSV Candidates ABI-1179 and ABI-5366
ASMB
New Projects/Investments
Guidance Update
- Assembly Biosciences, Inc. announced positive interim results from Phase 1b clinical studies of its investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-1179 and ABI-5366, for recurrent genital herpes.
- The 50 mg weekly oral dose of ABI-1179 demonstrated a 98% reduction in HSV-2 shedding rate and a 91% reduction in virologically confirmed genital lesion rate compared to placebo.
- The monthly oral dose of ABI-5366 showed a 76% reduction in HSV-2 shedding rate and an 88% reduction in virologically confirmed genital lesion rate compared to placebo.
- The company plans to initiate Phase 2 clinical studies for once-weekly ABI-5366 regimens in mid-2026 and is evaluating advancing ABI-1179 into Phase 2 clinical evaluation.
Dec 8, 2025, 9:17 PM
Assembly Biosciences Reports Positive Interim Phase 1b Results for HSV Inhibitors
ASMB
New Projects/Investments
- Assembly Biosciences announced positive interim results from two Phase 1b studies for its investigational long-acting herpes simplex virus (HSV) helicase-primase inhibitors, ABI-1179 and ABI-5366, on December 8, 2025.
- The 50 mg weekly oral dose of ABI-1179 demonstrated a 98% reduction in HSV-2 shedding rate and a 91% reduction in virologically confirmed genital lesion rate.
- The monthly oral dose of ABI-5366 showed a 76% reduction in HSV-2 shedding rate and an 88% reduction in virologically confirmed genital lesion rate.
- Both ABI-1179 and ABI-5366 were observed to be well-tolerated in their respective studies. Assembly Bio plans to initiate longer-duration Phase 2 clinical studies for once-weekly ABI-5366 regimens in mid-2026 and is evaluating ABI-1179 for Phase 2 clinical evaluation.
- Gilead Sciences, Inc. has the right to opt in for an exclusive license for further development and commercialization of the helicase-primase inhibitor program.
Dec 8, 2025, 9:05 PM
Assembly Biosciences Provides Update on Herpes Virus Pipeline and Financial Outlook
ASMB
New Projects/Investments
Guidance Update
- Assembly Biosciences (ASMB) is now primarily focused on herpes virus treatments, with lead assets 5366 and 1179 for high recurrent genital herpes, both currently in phase 1b trials.
- The company reported very positive interim data for 5366 in August, demonstrating over 90% reduction in shedding rate and greater than 90% reduction in lesions with once-a-week treatment, and the molecule has shown to be very well tolerated.
- Upcoming data in December will include unblinded safety data for 5366, data for a monthly regimen of 5366, and initial data for 1179 from its phase 1b study.
- The U.S. market for recurrent genital herpes is estimated at 1.3-1.4 million patients, with over 800,000 on chronic suppressive therapy, indicating a multi-billion dollar opportunity.
- ASMB's cash position is just north of $230 million, providing a runway to the end of 2027, potentially beyond 2028 with Gilead contributions and opt-in decisions for HBV and HSV-2 programs.
Nov 12, 2025, 4:00 PM
Assembly Biosciences Reports Q3 2025 Financial Results and Positive Clinical Trial Updates
ASMB
Earnings
Guidance Update
New Projects/Investments
- Assembly Biosciences reported a net loss of $9.2 million, or $0.72 per basic and diluted share, for the third quarter ended September 30, 2025, with revenue from collaborative research increasing to $10.8 million compared to $6.8 million in the same period of 2024.
- The company's cash, cash equivalents, and marketable securities totaled $232.6 million as of September 30, 2025, an increase from $75.0 million as of June 30, 2025, largely due to $175 million in gross proceeds from equity financings. This cash position is projected to fund operations into late 2027.
- Assembly Biosciences released positive interim Phase 1b results for ABI-5366 in recurrent genital herpes and interim Phase 1a results for ABI-6250 for HDV, supporting progression to Phase 2 clinical evaluation. Additional HSV program data readouts are anticipated by the end of the year.
Nov 10, 2025, 9:10 PM
Assembly Biosciences Presents Positive Phase 1b Data for ABI-4334
ASMB
New Projects/Investments
- Assembly Biosciences announced positive Phase 1b clinical data for its next-generation investigational capsid assembly modulator ABI-4334 at The Liver Meeting® on November 7, 2025.
- The study showed that ABI-4334 was well tolerated at both 150 mg and 400 mg oral doses given once-daily over 28 days in patients with chronic hepatitis B infection.
- Treatment with ABI-4334 resulted in multi-log declines in hepatitis B virus (HBV) DNA and pregenomic RNA (pgRNA), indicating potent suppression of viral replication.
- Gilead Sciences, Inc. has the right to opt in to an exclusive license for further development and commercialization of ABI-4334 after reviewing an option data package following completion of this Phase 1b study.
Nov 7, 2025, 1:00 PM
Assembly Biosciences Presents Positive Interim Phase 1b Data for ABI-5366
ASMB
New Projects/Investments
- Assembly Biosciences announced on October 10, 2025, that interim Phase 1b clinical data for its long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate ABI-5366 were presented at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe.
- In the 350 mg weekly dosing cohort, ABI-5366 demonstrated statistically significant reductions compared to placebo, including a 94% decrease in HSV type 2 (HSV-2) shedding rate, a 98% decrease in high viral load shedding rate, and a 94% decrease in genital lesion rate.
- ABI-5366 was observed to be well tolerated at both evaluated doses, and its pharmacokinetic profile supports weekly and potentially monthly dosing.
- Assembly Bio expects to share further interim data for a monthly dosing regimen of ABI-5366 and for ABI-1179 (another HSV helicase-primase inhibitor candidate) later this fall, with Phase 2 clinical studies of ABI-5366 anticipated to begin in mid-2026.
- Under a collaboration agreement, Gilead Sciences, Inc. has the right to opt in to an exclusive license for the helicase-primase inhibitor program after reviewing the option data package following completion of the Phase 1b studies.
Oct 10, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more